NASDAQ:SMMT - SUMMIT THERAPEU/S Stock Price, Forecast & News

SUMMIT THERAPEU/S trades on the NASDAQ under the ticker symbol "SMMT."

SUMMIT THERAPEU/S (NASDAQ:SMMT) issued its earnings results on Tuesday, December, 17th. The company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.02. The company had revenue of $0.16 million for the quarter, compared to analysts' expectations of $4.07 million. SUMMIT THERAPEU/S had a negative return on equity of 59.95% and a negative net margin of 2,107.69%. View SUMMIT THERAPEU/S's Earnings History.

SUMMIT THERAPEU/S is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for SUMMIT THERAPEU/S.

2 brokers have issued 12-month price targets for SUMMIT THERAPEU/S's stock. Their forecasts range from $2.00 to $2.00. On average, they expect SUMMIT THERAPEU/S's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 37.0% from the stock's current price. View Analyst Price Targets for SUMMIT THERAPEU/S.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SUMMIT THERAPEU/S in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for SUMMIT THERAPEU/S.

Media coverage about SMMT stock has trended very positive recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SUMMIT THERAPEU/S earned a media sentiment score of 3.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for SUMMIT THERAPEU/S.

Some companies that are related to SUMMIT THERAPEU/S include Spero Therapeutics (SPRO), GlycoMimetics (GLYC), Akorn (AKRX), Ovid Therapeutics (OVID), Neptune Wellness Solutions (NEPT), Tyme Technologies (TYME), Northwest Biotherapeutics (NWBO), ContraFect (CFRX), OASMIA PHARMACE/ADR (OASM), Avenue Therapeutics (ATXI), Marinus Pharmaceuticals (MRNS), Harrow Health (HROW), Adamas Pharmaceuticals (ADMS), Selecta Biosciences (SELB) and Aptinyx (APTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other SUMMIT THERAPEU/S investors own include Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Energy Transfer LP Unit (ET), Sorrento Therapeutics (SRNE), Catabasis Pharmaceuticals (CATB), Dynavax Technologies (DVAX), Viking Therapeutics (VKTX), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER) and Martin Midstream Partners (MMLP).

(SMMT) raised $40 million in an initial public offering (IPO) on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

SUMMIT THERAPEU/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.59%), Acadian Asset Management LLC (0.41%), First Republic Investment Management Inc. (0.16%) and Virtu Financial LLC (0.05%).

SMMT stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC.

SMMT stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Republic Investment Management Inc. and Virtu Financial LLC.

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of SMMT stock can currently be purchased for approximately $1.46.

SUMMIT THERAPEU/S has a market capitalization of $46.87 million and generates $56.50 million in revenue each year. The company earns $9.99 million in net income (profit) each year or $0.84 on an earnings per share basis. SUMMIT THERAPEU/S employs 61 workers across the globe.View Additional Information About SUMMIT THERAPEU/S.

The official website for SUMMIT THERAPEU/S is http://www.summitplc.com/.

SUMMIT THERAPEU/S's mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 44-12-3544-3939 or via email at [email protected]